{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:57:30Z","timestamp":1773442650291,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Adrenal gland metastases are a common diagnostic finding in various tumor diseases. Due to the increased use of imaging methods, they are diagnosed more frequently, especially in asymptomatic patients. SBRT has emerged as a new, alternative treatment option in the field of radiation oncology. In the past, it was often used for treating inoperable lung, liver, prostate, and brain tumors. Meanwhile, it is also an established keystone in the treatment of oligometastatic diseases. This retrospective study aims to evaluate the effect of low-dose SBRT in patients with adrenal metastases.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We analyzed a group of 31 patients with 34 adrenal gland lesions treated with low-dose SBRT between July 2006 and July 2019. Treatment-planning was performed through contrast-enhanced CT, followed by image-guided stereotactic radiotherapy using cone-beam CT. The applied cumulative median dose was 35\u2009Gy; the median single dose was 7\u2009Gy. We focused on local control (LC), progression-free survival (PFS), overall survival (OS), as well as acute and late toxicity.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Seven adrenal gland metastases (20.6%) experienced local failure, 80.6% of the patients faced a distant progression. Fourteen patients were still alive. Median follow-up for all patients was 9.8\u2009months and for patients alive 14.4\u2009months. No treatment-related side-effects &gt;grade 2 occurred. Of all, 48.4% suffered from acute gastrointestinal disorders; 32.3% reported acute fatigue, throbbing pain in the renal area, and mild adrenal insufficiency. Altogether, 19.4% of the patients faced late-toxicities, which were as follows: Grade 1: 12.9% gastrointestinal disorders, 3.2% fatigue, Grade 2: 9.7% fatigue, 6.5% headache, 3.2% loss of weight. The 1-year OS and probability of LF were 64 and 25.9%, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Low-dose SBRT has proven as an effective and safe method with promising outcomes for treating adrenal metastases. There appeared no high-grade toxicities &gt;grade 2, and 79.4% of treated metastases were progression-free. Thus, SBRT should be considered as a therapy option for adrenal metastases as an individual therapeutic concept in the interdisciplinary discussion as an alternative to surgical or systemic treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07030-w","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T14:05:17Z","timestamp":1591625117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-4593","authenticated-orcid":false,"given":"Theresa","family":"Voglhuber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin A.","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Oechsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco M. E.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"7030_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/1097-0142(19900101)65:1<177::AID-CNCR2820650134>3.0.CO;2-8","volume":"65","author":"AW Kung","year":"1990","unstructured":"Kung AW, Pun KK, Lam K, et al. Addisonian crisis as presenting feature in malignancies. Cancer. 1990;65:177\u20139.","journal-title":"Cancer."},{"issue":"12","key":"7030_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1055\/s-2005-921091","volume":"37","author":"I Ilias","year":"2005","unstructured":"Ilias I, Pacak K. Diagnosis and Management of Tumors of the adrenal medulla. Horm Metab Res. 2005;37(12):717\u201321.","journal-title":"Horm Metab Res"},{"key":"7030_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11934-009-0012-0","volume":"10","author":"J Uberoi","year":"2009","unstructured":"Uberoi J, Munver R. Surgical Management of Metastases to the adrenal gland: open, laparoscopic, and ablative approaches. Curr Urol Rep. 2009;10:67\u201372.","journal-title":"Curr Urol Rep"},{"key":"7030_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1046\/j.0300-0664.2001.01435.x","volume":"56","author":"KY Lam","year":"2002","unstructured":"Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol. 2002;56:95\u2013101.","journal-title":"Clin Endocrinol"},{"key":"7030_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7","volume":"3","author":"HL Abrams","year":"1950","unstructured":"Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer. 1950;3:74\u201385.","journal-title":"Cancer."},{"key":"7030_CR6","doi-asserted-by":"crossref","unstructured":"Zhao X, Zhu X, Fei J, et al. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer. Rad Oncol. 2018;13(1):205.","DOI":"10.1186\/s13014-018-1152-5"},{"key":"7030_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/1097-0142(19900315)65:6<1318::AID-CNCR2820650611>3.0.CO;2-H","volume":"65","author":"EM Soffen","year":"1990","unstructured":"Soffen EM, Solin LJ, Rubenstein JH, et al. Palliative Radiotherapy for Symptomatic Adrenal Metastases. Cancer. 1990;65:1318\u201320.","journal-title":"Cancer"},{"key":"7030_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.rpor.2015.05.009","volume":"20","author":"E Ippolito","year":"2015","unstructured":"Ippolito E, D\u2019Angelillo RM, Fiore M, et al. SBRT: a viable option for treating adrenal gland metastases. Rep Pract Oncol Radiother. 2015;20:484\u201390.","journal-title":"Rep Pract Oncol Radiother"},{"key":"7030_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jvir.2013.12.013","volume":"25","author":"BT Welch","year":"2014","unstructured":"Welch BT, Callstrom MR, Carpenter PC, et al. A single-institution experience in image-guided thermal ablation of adrenal gland metastases. J Vasc Interv Radiol. 2014;25:593\u20138.","journal-title":"J Vasc Interv Radiol"},{"issue":"17","key":"7030_CR10","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.4103\/0366-6999.210496","volume":"130","author":"EI Botsa","year":"2017","unstructured":"Botsa EI, Thanou IL, Papatheodoropoulou AT, et al. Thermal ablation in the Management of Adrenal Metastasis Originating from non-small cell lung Cancer: a 5-year single-center experience. Chin Med J. 2017;130(17):2027\u201332.","journal-title":"Chin Med J"},{"key":"7030_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1148\/radiol.2015142029","volume":"277","author":"T Hasegawa","year":"2015","unstructured":"Hasegawa T, Yamakado K, Nakatsuka A, et al. Unresectable adrenal metastases: clinical outcomes of radiofrequency ablation. Radiology. 2015;277:584\u201393.","journal-title":"Radiology."},{"key":"7030_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/icvts\/ivw321","volume":"24","author":"XL Gao","year":"2017","unstructured":"Gao XL, Zhang KW, Tang MB, et al. Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2017;24:1\u20137.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"7030_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.adro.2018.05.006","volume":"3","author":"DAS Toesca","year":"2018","unstructured":"Toesca DAS, Koong AJ, von Eyben R, et al. Stereotactic body radiation therapy for adrenal gland metastases: outcomes and toxicity. Adv Rad Oncol. 2018;3:621\u20139.","journal-title":"Adv Rad Oncol"},{"key":"7030_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.7785\/tcrt.2012.500320","volume":"12","author":"S Rudra","year":"2013","unstructured":"Rudra S, Malik R, Ranck MC, et al. Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat. 2013;12:217\u201324.","journal-title":"Technol Cancer Res Treat"},{"issue":"23","key":"7030_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/1078-0432.CCR-15-0822","volume":"21","author":"DA Palma","year":"2015","unstructured":"Palma DA, Louie AV, Rodrigues GB. New strategies in stereotactic radiotherapy for Oligometastases. Clin Cancer Res. 2015;21(23):198\u2013204.","journal-title":"Clin Cancer Res"},{"key":"7030_CR16","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1002\/cncr.26611","volume":"118","author":"JK Salama","year":"2012","unstructured":"Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer. 2012;118:2962\u201370.","journal-title":"Cancer."},{"issue":"1","key":"7030_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1120\/jacmp.v15i1.4600","volume":"15","author":"AC Riegel","year":"2014","unstructured":"Riegel AC, Kara Bucci M, Mawlawi OR, et al. Defining internal target volume using positron emission tomography for radiation therapy planning of moving lung tumors. J Appl Clin Med Phys. 2014;15(1):279\u201389.","journal-title":"J Appl Clin Med Phys"},{"key":"7030_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2016.03.019","volume":"96","author":"A Sindoni","year":"2016","unstructured":"Sindoni A, Minutoli F, Pontoriero A, et al. Usefulness of four dimensional (4D) PET\/CT imaging in the evaluation of thoracic lesions and in radiotherapy planning: review of the literature. Lung Cancer. 2016;96:78\u201386.","journal-title":"Lung Cancer"},{"issue":"4","key":"7030_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40(4):381\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"7030_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.radonc.2018.09.007","volume":"130","author":"A Dutz","year":"2019","unstructured":"Dutz A, Lock S. Competing risks in survival data analysis. Radiother Oncol. 2019;130:185\u20139.","journal-title":"Radiother Oncol"},{"issue":"3","key":"7030_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","volume":"70","author":"C Park","year":"2008","unstructured":"Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(3):847\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7030_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4143\/crt.2016.057","volume":"49","author":"C Franzese","year":"2017","unstructured":"Franzese C, Franceschini D, Cozzi L, et al. Minimally invasive Stereotactical Radio-ablation of Adrenal Metastases as an alternative to surgery. Cancer Res Treat. 2017;49:20\u20138.","journal-title":"Cancer Res Treat"},{"key":"7030_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/COC.0b013e3182569189","volume":"36","author":"KA Ahmed","year":"2013","unstructured":"Ahmed KA, Barney BM, Macdonald K, et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013;36:509\u201313.","journal-title":"Am J Clin Oncol"},{"key":"7030_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.adro.2017.07.011","volume":"2","author":"K Plichta","year":"2017","unstructured":"Plichta K, Camden N, Furqan M, et al. SBRT to adrenal metastases provides high local control with minimal toxicity. Adv Rad Oncol. 2017;2:581\u20137.","journal-title":"Adv Rad Oncol."},{"issue":"1","key":"7030_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13014-020-1480-0","volume":"15","author":"L K\u00f6nig","year":"2020","unstructured":"K\u00f6nig L, Hafner MF, Katayama S, et al. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiat Oncol. 2020;15(1):30.","journal-title":"Radiat Oncol"},{"key":"7030_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1245\/s10434-014-3750-2","volume":"22","author":"A Hauch","year":"2015","unstructured":"Hauch A, Al-Qurayshi Z, Kandil E. Factors associated with higher risk of complications after adrenal surgery. Ann Surg Oncol. 2015;22:103\u201310.","journal-title":"Ann Surg Oncol"},{"key":"7030_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/archsurg.1995.01430050039006","volume":"130","author":"RA Prinz","year":"1995","unstructured":"Prinz RA. A comparison of laparoscopic and open adrenalectomies. Arch Surg. 1995;130:489\u201392.","journal-title":"Arch Surg"},{"key":"7030_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/PL00012314","volume":"23","author":"CD Smith","year":"1999","unstructured":"Smith CD, Weber C, Amerson RJ. Laparoscopic Adrenalectomy: new gold standard. World J Surg. 1999;23:389\u201396.","journal-title":"World J Surg"},{"key":"7030_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3348\/kjr.2016.17.6.864","volume":"17","author":"M Men","year":"2016","unstructured":"Men M, Ye X, Fan W, et al. Short-term outcomes and safety of computed tomography-guided percutaneous microwave ablation of solitary adrenal metastasis from lung Cancer: a multi-center retrospective study. Korean J Radiol. 2016;17:864\u201373.","journal-title":"Korean J Radiol"},{"key":"7030_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.prro.2011.11.002","volume":"2","author":"RW Eldaya","year":"2012","unstructured":"Eldaya RW, Paulino AC, Blanco AI, et al. Preservation of adrenal function after successful stereotactic body radiation therapy of metastatic renal cell carcinoma involving the remaining contralateral adrenal gland. Pract Rad Oncol. 2012;2:270\u20133.","journal-title":"Pract Rad Oncol"},{"issue":"3","key":"7030_CR31","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.prro.2016.09.005","volume":"7","author":"WW Chance","year":"2017","unstructured":"Chance WW, Nguyen QN, Mehran R, et al. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017;7(3):e195\u2013203.","journal-title":"Pract Radiat Oncol"},{"key":"7030_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00066-011-2192-z","volume":"187","author":"R Holy","year":"2011","unstructured":"Holy R, Piroth M, Pinkawa M, et al. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung Cancer. Strahlenther Onkol. 2011;187:245\u201351.","journal-title":"Strahlenther Onkol"},{"key":"7030_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/jcrt.JCRT_655_16","volume":"15","author":"MM Shah","year":"2019","unstructured":"Shah MM, Isrow D, Fareed MM, et al. Single institution experience treating adrenal metastases with stereotactic body radiation therapy. J Can Res Ther. 2019;15:27\u201332.","journal-title":"J Can Res Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07030-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:32:39Z","timestamp":1623108759000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07030-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7030"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07030-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"19 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Analysis of patient records and data collection took place after being approved by the local ethics committee of the Technical University Munich (TUM), vote number 307\/19.The ethics vote for this retrospective analysis is available in writing. No other form of explicit informed consent was necessary.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"536"}}